Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant

Animals Carbapenems / therapeutic use Ertapenem / therapeutic use Extensively Drug-Resistant Tuberculosis / drug therapy Female Imipenem / therapeutic use Meropenem / therapeutic use Mice Mice, Inbred BALB C Mice, Inbred C57BL Mycobacterium tuberculosis / drug effects Prospective Studies
carbapenems clinical ertapenem imipenem in vitro in vivo meropenem tuberculosis

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
02 2019
Historique:
received: 17 07 2018
accepted: 07 11 2018
pubmed: 21 11 2018
medline: 28 1 2020
entrez: 21 11 2018
Statut: epublish

Résumé

Multi- and extensively drug-resistant tuberculosis (M/XDR-TB) has become an increasing threat not only in countries where the TB burden is high but also in affluent regions, due to increased international travel and globalization. Carbapenems are earmarked as potentially active drugs for the treatment of

Identifiants

DOI: 10.1128/AAC.01489-18 PMID: 30455232 PMC: PMC6355583
pubmed: 30455232
pii: AAC.01489-18
doi: 10.1128/AAC.01489-18
pmc: PMC6355583
pii:
doi:

Substances chimiques

Carbapenems 0
Imipenem 71OTZ9ZE0A
Meropenem FV9J3JU8B1
Ertapenem G32F6EID2H

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2019 American Society for Microbiology.

Références

Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28137814
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3193-5
pubmed: 26926650
Sci Adv. 2017 Aug 30;3(8):e1701102
pubmed: 28875168
Biochemistry. 2007 Oct 30;46(43):11998-2004
pubmed: 17915954
Antimicrob Agents Chemother. 2013 Dec;57(12):6085-96
pubmed: 24060876
Antimicrob Agents Chemother. 2012 Jun;56(6):3384-7
pubmed: 22450968
Eur Respir J. 2015 Aug;46(2):444-55
pubmed: 26022960
Clin Infect Dis. 2008 Sep 15;47 Suppl 1:S32-40
pubmed: 18713048
Eur Respir J. 2017 Mar 22;49(3):
pubmed: 28331043
J Bacteriol. 2008 Jun;190(12):4360-6
pubmed: 18408028
J Biol Chem. 2015 Oct 16;290(42):25670-85
pubmed: 26304120
Clin Infect Dis. 2016 Nov 1;63(suppl 3):S102-S109
pubmed: 27742641
Rev Port Pneumol (2006). 2016 Nov - Dec;22(6):337-341
pubmed: 27481315
Antimicrob Agents Chemother. 2005 Jul;49(7):2816-21
pubmed: 15980354
Eur Respir J. 2013 Jun;41(6):1386-92
pubmed: 22997218
Antimicrob Agents Chemother. 2011 Jun;55(6):2597-600
pubmed: 21402832
Tuber Lung Dis. 1992 Jun;73(3):134-6
pubmed: 1421344
mBio. 2010 Aug 10;1(3):
pubmed: 20802826
Antimicrob Agents Chemother. 2013 Jun;57(6):2506-10
pubmed: 23507276
Arch Bronconeumol. 2015 Oct;51(10):e49-52
pubmed: 26026689
Lancet Respir Med. 2018 Apr;6(4):e11-e12
pubmed: 29396032
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28696238
Antimicrob Agents Chemother. 1995 Dec;39(12):2620-4
pubmed: 8592990
Eur Respir J. 2016 Apr;47(4):1229-34
pubmed: 26743484
Antimicrob Agents Chemother. 2012 Jun;56(6):3409-12
pubmed: 22450984
Eur Respir J. 2016 Jan;47(1):333-6
pubmed: 26585427
J Antimicrob Chemother. 2017 Jul 1;72(7):2012-2019
pubmed: 28333342
Int J Tuberc Lung Dis. 2012 Apr;16(4):558-60
pubmed: 22325421
J Antimicrob Chemother. 2013 Feb;68(2):366-9
pubmed: 23070734
Antimicrob Agents Chemother. 2015 Oct;59(10):6561-7
pubmed: 26259792
ACS Chem Biol. 2013;8(6):1140-6
pubmed: 23574509
Antimicrob Agents Chemother. 2015 Nov 02;60(1):393-9
pubmed: 26525785
Antimicrob Agents Chemother. 2015 Feb;59(2):1308-19
pubmed: 25421469
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29180526
Antimicrob Agents Chemother. 2014 Nov;58(11):7010-4
pubmed: 25224000
Clin Infect Dis. 2018 May 2;66(10):1625-1630
pubmed: 29126225
Mol Microbiol. 2012 Oct;86(2):367-81
pubmed: 22906310
Antimicrob Agents Chemother. 1983 Sep;24(3):429-31
pubmed: 6416162
Acta Crystallogr D Biol Crystallogr. 2013 Mar;69(Pt 3):420-31
pubmed: 23519417
Infect Dis Clin North Am. 2003 Sep;17(3):479-501
pubmed: 14711073
PLoS One. 2013 Jul 04;8(7):e67831
pubmed: 23861815
J Infect Dis. 2004 Nov 1;190(9):1642-51
pubmed: 15478070
Clin Infect Dis. 2016 Nov 1;63(suppl 3):S95-S101
pubmed: 27742640
Antimicrob Agents Chemother. 2018 Apr 26;62(5):
pubmed: 29439978
J Bacteriol. 2014 Apr;196(7):1394-402
pubmed: 24464457
Antimicrob Agents Chemother. 2015 Aug;59(8):4997-9
pubmed: 25987618
Nat Chem Biol. 2017 Jan;13(1):54-61
pubmed: 27820797
Antimicrob Agents Chemother. 2013 Dec;57(12):5940-5
pubmed: 24041897
Antimicrob Agents Chemother. 2010 Oct;54(10):4150-8
pubmed: 20679505
Eur Respir J. 2016 Jun;47(6):1758-66
pubmed: 27076583
J Antimicrob Chemother. 2017 Aug 1;72(8):2320-2325
pubmed: 28575382
Eur Respir J. 2016 Apr;47(4):1235-43
pubmed: 26965290
Structure. 2012 Dec 5;20(12):2103-15
pubmed: 23103390
Science. 2009 Feb 27;323(5918):1215-8
pubmed: 19251630
Antimicrob Agents Chemother. 2015;59(6):3630-2
pubmed: 25824227
J Biol Chem. 2011 Jul 1;286(26):22777-84
pubmed: 21543331
Int J Tuberc Lung Dis. 2018 Jan 1;22(1):34-39
pubmed: 29297423
J Antimicrob Chemother. 2017 Jun 1;72(6):1678-1687
pubmed: 28333192
Eur Respir J. 2014 Mar;43(3):884-97
pubmed: 23988774
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Antimicrob Agents Chemother. 2012 Aug;56(8):4189-95
pubmed: 22615283
EBioMedicine. 2016 Jul;9:170-179
pubmed: 27333036
Eur Respir J. 2017 Jul 27;50(1):
pubmed: 28751411
Clin Infect Dis. 2016 May 1;62(9):1188-90
pubmed: 26908794
Clin Infect Dis. 2015 Aug 15;61 Suppl 1:S1-4
pubmed: 26224766

Auteurs

Sander P van Rijn (SP)

University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.

Marlanka A Zuur (MA)

University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.

Richard Anthony (R)

National Institute for Public Health and the Environment, National Mycobacteria Reference Laboratory, Bilthoven, The Netherlands.

Bob Wilffert (B)

University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
University of Groningen, Groningen Research Institute of Pharmacy, Unit of Pharmacotherapy, Epidemiology & Pharmacoeconomics, Groningen, The Netherlands.

Richard van Altena (R)

University of Groningen, University Medical Center Groningen, Tuberculosis Centre Beatrixoord, Haren, The Netherlands.
University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.

Onno W Akkerman (OW)

University of Groningen, University Medical Center Groningen, Tuberculosis Centre Beatrixoord, Haren, The Netherlands.
University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.

Wiel C M de Lange (WCM)

University of Groningen, University Medical Center Groningen, Tuberculosis Centre Beatrixoord, Haren, The Netherlands.
University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.

Tjip S van der Werf (TS)

University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.
University of Groningen, University Medical Center Groningen, Department of Internal Medicine, Groningen, The Netherlands.

Jos G W Kosterink (JGW)

University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
University of Groningen, Groningen Research Institute of Pharmacy, Unit of Pharmacotherapy, Epidemiology & Pharmacoeconomics, Groningen, The Netherlands.

Jan-Willem C Alffenaar (JC)

University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands j.w.c.alffenaar@umcg.nl.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Meal Timing and Anthropometric and Metabolic Outcomes: A Systematic Review and Meta-Analysis.

Hiu Yee Liu, Ashley A Eso, Nathan Cook et al.
1.00
Humans Meals Time Factors Female Adult

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Evaluation of Carbapenems for Treatment of...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Carbapénèmes › Evaluation of Carbapenems for Treatment of...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Carbapénèmes › Ertapénem › Evaluation of Carbapenems for Treatment of...
questionsmedicales.fr › Infection › Infections bactériennes et mycoses › Infections bactériennes › Infections bactériennes à Gram positif › Infections à Actinomycetales › Infections à Mycobacterium › Tuberculose › Tuberculose multirésistante › Tuberculose ultrarésistante aux médicaments › Evaluation of Carbapenems for Treatment of...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Carbapénèmes › Thiénamycine › Imipénem › Evaluation of Carbapenems for Treatment of...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Carbapénèmes › Thiénamycine › Méropénème › Evaluation of Carbapenems for Treatment of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Evaluation of Carbapenems for Treatment of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée BALB C › Evaluation of Carbapenems for Treatment of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Lignées consanguines de souris › Souris de lignée C57BL › Evaluation of Carbapenems for Treatment of...
questionsmedicales.fr › Bactéries › Bactéries à Gram positif › Bâtonnets à Gram positif › Bâtonnets asporogènes à Gram positif › Bâtonnets asporogènes réguliers à Gram positif › Mycobacteriaceae › Mycobacterium › Mycobacterium tuberculosis › Evaluation of Carbapenems for Treatment of...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Evaluation of Carbapenems for Treatment of...